此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Effect of Sinetrol on Body Composition &Metabolic Health in Peri-menopausal/Early Menopausal Women (MENOFIT)

2026年8月20日 更新者:DR Healthcare - biotexia

A Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Effect of Sinetrol on Body Composition &Metabolic Health in Peri-menopausal/Early Menopausal Women (MENOFIT)

The menopausal transition is associated with significant hormonal and metabolic changes, primarily driven by a decline in estrogen levels. These changes contribute to alterations in body composition, including an increase in total body fat, preferential accumulation of central and visceral adipose tissue, and a reduction in lean body mass. Such redistribution of adiposity is a defining feature of peri- and early postmenopausal stages and is closely linked to increased cardiometabolic risk.

Visceral adipose tissue is metabolically active and contributes to the development of insulin resistance, dyslipidemia, and chronic low-grade inflammation through the secretion of pro-inflammatory cytokines and adipokines.These metabolic alterations may adversely impact overall health, physical function, and quality of life in peri- and postmenopausal women. In addition, menopause-associated changes in energy expenditure and appetite regulation may further predispose individuals to weight gain and fat accumulation.

Conventional management strategies for weight gain during menopause include lifestyle interventions such as dietary modification and physical activity; however, long-term adherence to these approaches is often limited. Pharmacological options may also be associated with safety concerns or may not directly address body composition changes. Therefore, there is increasing interest in nutraceutical approaches that may safely support metabolic health and body composition in this population.6 Sinetrol XPur C is a standardized polyphenolic extract derived from citrus fruits, including red orange, grapefruit, and sweet orange, enriched with flavonoids such as naringin and hesperidin. These bioactive compounds have been shown to influence lipid metabolism and adipocyte function.

Clinical studies have demonstrated the potential of Sinetrol XPur C in supporting body composition management.

The available clinical evidence suggests that Sinetrol XPur C may support body composition and metabolic health through mechanisms involving enhanced lipolysis, improved energy metabolism, and modulation of adipose tissue function.

Given the physiological changes associated with menopause and the need for safe and effective interventions, Sinetrol XPur C may represent a promising nutritional approach for improving body composition and related metabolic parameters in peri- and early postmenopausal women.

The study objective is to assess the effect of Sinetrol XPur C on Body composition (Total fat mass and fat free mass) using Dual-Energy- X-ray Absorptiometry (DEXA) when compared to baseline and placebo.

研究概览

研究类型

介入性

注册 (估计的)

200

阶段

  • 不适用

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria:

  • perimenopausal or early menopausal women

Exclusion Criteria:

  • women under HRT treatment

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂
麦芽糊精
dietary supplementation
有源比较器:investigational product
Sinetrol 630 mg/capsule/day
dietary supplementation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Body composition (Total fat mass and fat free mass) when compared to baseline and placebo.
大体时间:180 days
To assess the effect of Sinetrol XPur C on Body composition (Total fat mass and fat free mass) using Dual-Energy- X-ray Absorptiometry (DEXA) when compared to baseline and placebo.
180 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2028年8月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年8月20日

首先提交符合 QC 标准的

2026年8月20日

首次发布 (实际的)

2026年8月24日

研究记录更新

最后更新发布 (实际的)

2026年8月24日

上次提交的符合 QC 标准的更新

2026年8月20日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • MENOFIT

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅